Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Edgewise Therapeutics Inc...

    NASDAQ: EWTX · Real-Time Price · USD
    16.70
    -0.21 (-1.24%)
    At close: May 05, 2025, 12:20 PM
    -1.24%
    Bid 16.64
    Market Cap 1.76B
    Revenue (ttm) n/a
    Net Income (ttm) -133.81M
    EPS (ttm) -1.45
    PE Ratio (ttm) -11.51
    Forward PE -7.77
    Analyst Buy
    Ask 16.73
    Volume 260,969
    Avg. Volume (20D) 1,825,960
    Open 16.64
    Previous Close 16.91
    Day's Range 16.38 - 16.91
    52-Week Range 10.60 - 38.12
    Beta 0.33

    About EWTX

    Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...

    [Read more]
    Industry Biotechnology
    Sector Healthcare
    IPO Date Mar 26, 2021
    Employees 110
    Stock Exchange NASDAQ
    Ticker Symbol EWTX
    Website https://www.edgewisetx.com
    Full Company Profile

    Analyst Forecast

    According to 8 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $46.5, which is an increase of 178.53% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -22.9%
    Edgewise Therapeutics shares are trading lower aft... Unlock content with Pro Subscription
    4 months ago
    +18.36%
    Edgewise Therapeutics shares are trading higher after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.
    news image

    2 days ago · fool.com

    Why Edgewise Therapeutics Stock Popped This Week

    On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compi...

    news image

    3 weeks ago · 247wallst.com

    These 5 Insiders Are Buying During Market Chaos

    Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade w...

    news image

    4 weeks ago · zacks.com

    EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

    Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

    news image

    1 month ago · seekingalpha.com

    Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

    The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook ...

    news image

    1 month ago · benzinga.com

    Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

    Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopa...

    news image

    1 month ago · investors.com

    Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

    Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks J...

    news image

    1 month ago · businesswire.com

    Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

    BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an i...

    news image

    1 month ago · seekingalpha.com

    Edgewise Therapeutics: More Expensive Now, But Much More Derisked

    Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targetin...

    news image

    2 months ago · businesswire.com

    Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

    BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners G...

    news image

    2 months ago · businesswire.com

    Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

    BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year ...

    Add to Watchlist